Immunocore Holdings plc
IMCRNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · X0 · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | |
|---|---|---|---|---|---|
| Revenue | $400.0M | $310.2M | $249.4M | $174.4M | $4.1M |
| Operating income | −$45.4M | −$70.5M | −$59.6M | −$51.7M | −$174.6M |
| Net income | −$35.5M | −$51.1M | −$55.3M | −$52.5M | −$180.0M |
| Total assets | $1.07B | $1.01B | $597.0M | $526.8M | — |
| Total liabilities | $686.2M | $648.8M | $228.2M | $187.9M | — |
| Equity | $381.0M | $360.7M | $368.8M | $338.9M | $233.7M |
| EPS (diluted) | $-0.71 | $-1.02 | $-1.13 | $-1.15 | $-4.24 |
| Shares out. | 50.1M | 49.8M | 49.7M | 48.1M | 42.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −11.3%
- Net margin
- −8.9%
- Return on equity
- −9.3%
- Return on assets
- −3.3%
- Return on capital (ROCE)
- −5.5%
- Liabilities / assets
- 64.3%
- Debt / equity
- 1.80×
- Book value / share
- $7.61
- Revenue growth (YoY)
- 29.0%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 2.37grey zone
- Accruals / assets
- −2.3%clean
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 4 warning● 2 good- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Altman Z″ in the grey zone
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1/2Active Not Recruitingreadout ~2026-10Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
- Phase 1/2Recruitingreadout ~2026-11-30Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers
- Phase 1Recruitingreadout ~2027-09-30Study of IMC-P115C in Advanced PRAME-Positive Cancers
- Phase 3Recruitingreadout ~2027-10-16IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
- Phase 3Recruitingreadout ~2028-03Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
- Phase 1Not Yet Recruitingreadout ~2030-11Study of IMC-S118AI in Type 1 Diabetes
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- T. Rowe Price Investment Management, Inc.Passive (13G)May 15, 2026
- Vestal Point Capital, LpPassive (13G)May 15, 2026
- Bellevue Group AgPassive (13G)Nov 14, 2025
- Tang Capital Management LlcPassive (13G)Oct 24, 2025
- Eli Lilly & CoPassive (13G)Oct 3, 2025
- Primecap Management Co/Ca/Passive (13G)Aug 14, 2025
- Wellington Management Group LlpPassive (13G)Aug 5, 2025
- Jallal BahijaPassive (13G)Feb 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Jallal BahijaOfficer — CHIEF EXECUTIVE OFFICER | Feb 17, 2026 | Option exercise | 23,817 | $0.00 |
| Goll JohnOfficer — SVP, FINANCE & CAO | Feb 17, 2026 | Option exercise | 1,351 | $0.00 |
| St Leger Tina AmberOfficer — CHIEF HR OFFICER | Feb 17, 2026 | Option exercise | 2,119 | $0.00 |
| Berman David MOfficer — HEAD OF R&D | Feb 17, 2026 | Option exercise | 11,824 | $0.00 |
| Berman David MOfficer — HEAD OF R&D | Dec 4, 2025 | Option exercise | 31,341 | $17.46 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 9.0M | 35.4 | +0.0% |
| Apr 30, 2026 | 9.0M | 20.8 | -8.3% |
| Apr 15, 2026 | 9.8M | 22.6 | -3.6% |
| Mar 31, 2026 | 10.1M | 26.1 | +0.1% |
| Mar 13, 2026 | 10.1M | 28.4 | -15.4% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Shareholder voteMay 27, 2026
- Results of operationsMay 6, 2026
- Results of operationsFeb 25, 2026
- Director / officer changeJan 30, 2026
- Results of operations · Regulation FD disclosure · Other material eventJan 9, 2026
- Director / officer changeNov 28, 2025
- Results of operationsNov 6, 2025
- Results of operationsAug 7, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.